Blue Chip Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
$911K Buy
26,167
+1,897
+8% +$66.5K 0.72% 36
2020
Q2
$753K Buy
24,270
+262
+1% +$8.9K 0.71% 39
2020
Q1
$743K Buy
24,008
+1,088
+5% +$37.1K 0.93% 33
2019
Q4
$852K Sell
22,920
-4,602
-17% -$164K 0.79% 36
2019
Q3
$938K Sell
27,522
-4,473
-14% -$163K 0.98% 31
2019
Q2
$1.31M Buy
31,995
+228
+0.7% +$9.05K 1.39% 22
2019
Q1
$1.28M Buy
31,767
+601
+2% +$24.1K 1.45% 21
2018
Q4
$1.29M Buy
31,166
+1,280
+4% +$53.1K 1.69% 17
2018
Q3
$1.25M Sell
29,886
-348
-1% -$13.4K 1.26% 23
2018
Q2
$1.04M Buy
30,234
+1,500
+5% +$51.3K 1.13% 28
2018
Q1
$968K Buy
+28,734
New +$988K 0.99% 30

Other funds holding PFE

Blue Chip Wealth Management's PFE Position: Q3 2020 in Review

Blue Chip Wealth Management increased its Pfizer (PFE) stake by 7.8% in Q3 2020, buying an estimated $66.5K and bringing the position to 26,167 shares worth $911K. The position accounts for 0.72% of the portfolio, ranked #36.

Blue Chip Wealth Management first reported a position in PFE in Q1 2018 and has held it in 11 quarters since. The position peaked at $1.31M in Q2 2019. 2,509 funds tracked by Wall St. Rank hold PFE as of Q3 2020.

  • Blue Chip Wealth Management held 26,167 shares of Pfizer worth $911K as of Q3 2020.
  • Blue Chip Wealth Management bought 1,897 Pfizer shares in Q3 2020, an estimated $66.5K.
  • Pfizer made up 0.72% of Blue Chip Wealth Management's portfolio in Q3 2020, its #36 holding.
  • Blue Chip Wealth Management first reported a position in Pfizer in Q1 2018 and has held it in 11 quarters since.
  • Blue Chip Wealth Management's Pfizer position peaked at $1.31M in Q2 2019.
  • 2,509 funds tracked by Wall St. Rank held Pfizer as of Q3 2020.

Based on Blue Chip Wealth Management's 13F filing for Q3 2020, filed 12 Nov 2020.